HOTH - Hoth Therapeutics slides on public offering of common stock

The development-stage pharmaceutical company Hoth Therapeutics (NASDAQ:HOTH) followed up its impressive preclinical data for its investigational cancer therapy, HT-KIT with the start of an underwritten public offering of common stock on Monday. Following the announcement, the shares of the New York-based company plunged in the post-market with a decline of 15% so far. The proposed offering is in line with a "shelf" registration statement filed by the company with the Securities and Exchange Commission (SEC) in March 2020.

For further details see:

Hoth Therapeutics slides on public offering of common stock